Harrow announced the re-launch of VERKAZIA, a prescription therapy for vernal keratoconjunctivitis (VKC), a chronic allergic eye disease primarily affecting children. The company is implementing a comprehensive commercial strategy focused on physician education, patient access, and affordability. VERKAZIA is a calcineurin inhibitor that addresses underlying inflammatory mechanisms and reduces the need for steroid rescue therapy, which carries risks like glaucoma and cataract formation.

Harrow (Nasdaq: HROW), a leading ophthalmic disease management solutions provider, announced that management will present at William Blair's 46th Annual Growth Stock Conference on June 3, 2026, in Chicago. The presentation will be webcast live with a 90-day replay available on the company's website.

Harrow (Nasdaq: HROW), an ophthalmic disease management solutions provider, announced a private offering of $50 million in 8.625% senior unsecured notes due 2030. The notes will be issued as additional notes under the same indenture as $250 million in existing notes issued in September 2025. The offering is expected to close on March 27, 2026, with net proceeds intended for general corporate purposes including new product launches, product development, and strategic business development opportunities.

Opaleye Management Inc., a 10% owner of ophthalmic pharma company Harrow, sold 198,572 shares worth $7.8 million on March 3-4, 2026. However, the fund retained approximately 3.7 million shares (nearly 10% ownership), suggesting this was a tactical profit-taking move following post-earnings weakness rather than a strategic exit.

Harrow announced it will report Q4 and full-year 2025 financial results on March 2, 2026, with a conference call scheduled for March 3, 2026. The company reaffirmed its 2025 full-year revenue guidance of $270-$280 million, indicating strong growth. Harrow is expanding its commercial footprint across multiple product lines including VEVYE, IHEEZO, and TRIESENCE.

Harrow reaffirmed its 2025 revenue guidance of $270-280 million and announced multiple growth initiatives including doubling its VEVYE sales force, expanding IHEEZO to office-based settings, and doubling TRIESENCE's surgical sales force. The company launched the OneHarrow initiative to unify branding, promoted Patrick W. Sullivan to Chief Commercial Officer, and advanced MELT-300 and MELT-210 toward NDA filings. ImprimisRx settled regulatory matters with California and exited the state market.

Penn Capital Management sold 1.6 million shares of BGC Group in Q3, reducing its stake to $5.9 million, despite the company reporting record quarterly revenue of $736.8 million, up 31% year-over-year.

Harrow Inc. announced the acquisition of Melt Pharmaceuticals, a clinical-stage company developing a non-opioid sedation tablet (MELT-300) for medical procedures. The company plans to submit a New Drug Application to the FDA in 2027, targeting a U.S. launch in 2028.

Harrow plans to acquire Melt Pharmaceuticals for its MELT-300 sedation therapy, a non-opioid sublingual medication designed to provide rapid sedation for medical procedures. The acquisition aims to expand Harrow's procedural sedation market presence and offer an alternative to traditional IV sedation.

Harrow is raising $250 million through senior unsecured notes due in 2030, with plans to repay existing debt and potentially fund future business development opportunities.

Harrow is issuing $250 million in senior unsecured notes due 2030 and entering a new $40 million revolving credit facility with Fifth Third Bank. The company plans to use proceeds to repay existing debt and redeem outstanding senior notes.

Pomerantz LLP is investigating potential securities fraud at Harrow, Inc. after the company missed financial estimates in Q1 2025, causing its stock price to drop 4.07%.